UnicoCell Biomed Co., Ltd. (TPE:6794)
Taiwan
· Delayed Price · Currency is TWD 82.00
-1.90 (-2.26%)
Mar 9, 2026, 1:34 PM CST
UnicoCell Biomed Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Revenue | 30.1 | 31.88 | 24.59 | 14.4 | 8.18 | Upgrade
|
| Revenue Growth (YoY) | -5.58% | 29.66% | 70.79% | 76.07% | 105.35% | Upgrade
|
| Cost of Revenue | 11.13 | 11.31 | 6.69 | 6.2 | 2.35 | Upgrade
|
| Gross Profit | 18.98 | 20.57 | 17.9 | 8.2 | 5.83 | Upgrade
|
| Selling, General & Admin | 41.6 | 34.85 | 31.4 | 25.4 | 23.3 | Upgrade
|
| Research & Development | 107.54 | 88.64 | 82.78 | 74.91 | 69.87 | Upgrade
|
| Operating Expenses | 149.26 | 123.49 | 114.18 | 100.31 | 93.17 | Upgrade
|
| Operating Income | -130.28 | -102.92 | -96.28 | -92.11 | -87.34 | Upgrade
|
| Interest Expense | -1.34 | -1.47 | -1.45 | -1.26 | -0.66 | Upgrade
|
| Interest & Investment Income | 9.36 | 7.54 | 5.79 | 0.84 | 0.08 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.02 | 0.01 | 0.05 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 7.43 | 5.13 | 3.04 | 1.18 | 1.54 | Upgrade
|
| EBT Excluding Unusual Items | -114.84 | -91.7 | -88.9 | -91.3 | -86.37 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -1.79 | - | 0.1 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.41 | 4.79 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 0.05 | - | Upgrade
|
| Pretax Income | -114.84 | -93.07 | -84.11 | -91.16 | -86.37 | Upgrade
|
| Net Income | -114.84 | -93.07 | -84.11 | -91.16 | -86.37 | Upgrade
|
| Net Income to Common | -114.84 | -93.07 | -84.11 | -91.16 | -86.37 | Upgrade
|
| Shares Outstanding (Basic) | 61 | 57 | 54 | 41 | 38 | Upgrade
|
| Shares Outstanding (Diluted) | 61 | 57 | 54 | 41 | 38 | Upgrade
|
| Shares Change (YoY) | 5.90% | 6.68% | 29.61% | 10.12% | 6.10% | Upgrade
|
| EPS (Basic) | -1.89 | -1.62 | -1.56 | -2.20 | -2.29 | Upgrade
|
| EPS (Diluted) | -1.89 | -1.62 | -1.56 | -2.20 | -2.29 | Upgrade
|
| Free Cash Flow | -96.81 | -66.84 | -81.35 | -78.05 | -85.34 | Upgrade
|
| Free Cash Flow Per Share | -1.59 | -1.17 | -1.51 | -1.88 | -2.27 | Upgrade
|
| Gross Margin | 63.04% | 64.52% | 72.78% | 56.93% | 71.32% | Upgrade
|
| Operating Margin | -432.77% | -322.83% | -391.56% | -639.78% | -1068.08% | Upgrade
|
| Profit Margin | -381.48% | -291.94% | -342.06% | -633.15% | -1056.30% | Upgrade
|
| Free Cash Flow Margin | -321.59% | -209.66% | -330.82% | -542.15% | -1043.70% | Upgrade
|
| EBITDA | -109.73 | -82.37 | -76.71 | -76.25 | -71.24 | Upgrade
|
| EBITDA Margin | - | -258.35% | - | - | - | Upgrade
|
| D&A For EBITDA | 20.55 | 20.56 | 19.57 | 15.86 | 16.1 | Upgrade
|
| EBIT | -130.28 | -102.92 | -96.28 | -92.11 | -87.34 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.